SEBI eases compliance rules for processing of demat request, KYC application

Markets regulator SEBI on Thursday relaxed compliance norms for depository participants, stock brokers and share transfer agents with regard to the processing of demat request and KYC application amid the coronavirus pandemic

Press Trust of India April 16, 2020 18:54:53 IST
SEBI eases compliance rules for processing of demat request, KYC application

New Delhi: Markets regulator SEBI on Thursday relaxed compliance norms for depository participants, stock brokers and share transfer agents with regard to the processing of demat request and KYC application amid the coronavirus pandemic.

The relaxation has been given till 3 May, the Securities and Exchange Board of India (SEBI) said in a circular.

The regulator has eased compliance requirements with regard to the processing of the demat request form by the issuer or registrar of share transfer agent (RTA) and depository participants.

SEBI eases compliance rules for processing of demat request KYC application

Representational image. Reuters.

Under the norms, processing of the demat request form by the issuer or RTA needs to be done within 15 days, while the same for depository participants within seven days.

Besides, it has relaxed guidelines for KYC (Know Your Client) application form and supporting documents of the client that need to be uploaded on the system of KRA (KYC registration agency) within 10 working days.

The period from 23 March till 17 May shall be excluded for computing the existing timelines for compliance, SEBI noted.

Further, a 15-day time period after 17 May has been allowed to the registered intermediary, to clear the backlog.

The decision has been taken in view of the situation arising due to COVID-19 pandemic and extended lockdown period as well as based on representations received from the depositories, it added.

Updated Date:

also read

China announces roll-back of strict anti-COVID-19 measures
World

China announces roll-back of strict anti-COVID-19 measures

In a sharp reversal, China has announced a series of measures rolling back some of the most draconian anti-COVID-19 restrictions.

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval
Health

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose

China eases controls, gives no sign when 'zero COVID' ends
World

China eases controls, gives no sign when 'zero COVID' ends

China is the only major country still trying to stamp out transmission while the United States and others relax restrictions and try to live with the virus that has killed at least 6.6 million people and infected almost 650 million